Filter Results:
(196)
Show Results For
- All HBS Web
(267)
- News (29)
- Research (196)
- Multimedia (2)
- Faculty Publications (103)
Show Results For
- All HBS Web
(267)
- News (29)
- Research (196)
- Multimedia (2)
- Faculty Publications (103)
Sort by
- 15 Jan 2008
- First Look
First Look: January 15, 2008
across complements can offset horizontal competition between substitutes. In this paper, we isolate the offsetting price effects and show how they operate in large (as well as small) clusters. We argue that it is possible in principle for... View Details
Keywords: Martha Lagace
- Research Summary
Regulatory Change/Business-Government Relations
“Sources of Learning Heterogeneity: Discontinuous Regulatory Shock and its Impact on Organizational Search Behaviors”
Co-authoring with Jerry Kim, in this study I look at how discontinuous regulatory shock shapes organizational... View Details
- June 1999 (Revised June 2000)
- Case
Eckerd Corporation
By: Michael E. Porter and John E. Kelleher
Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future. View Details
Keywords: Competition; Alignment; Supply and Industry; Pharmaceutical Industry; Pharmaceutical Industry
Porter, Michael E., and John E. Kelleher. "Eckerd Corporation." Harvard Business School Case 799-141, June 1999. (Revised June 2000.)
- 11 Sep 2007
- First Look
First Look: September 11, 2007
own profits when one side is subsidized in equilibrium. By contrast, if platforms make positive margins on both sides, the same investment has the regular, expected effects. Our analysis implies that the strategy space and the logic of View Details
Keywords: Martha Lagace
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Pharmaceutical Industry; Pharmaceutical Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- 15 May 2007
- First Look
First Look: May 15, 2007
Purchase this note: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=907412 HDFC (A) Harvard Business School Case 301-093 The top management team at India's leading home finance company must decide how to deal with the emergence of intense View Details
Keywords: Martha Lagace
- September–October 2020
- Article
Social-Impact Efforts That Create Real Value
By: George Serafeim
Until the mid-2010s few investors paid attention to environmental, social, and governance (ESG) data—information about companies’ carbon footprints, labor policies, board makeup, and so forth. Today the data is widely used by investors. How can organizations create... View Details
Keywords: Sustainability; Sustainability Management; ESG; ESG (Environmental, Social, Governance) Performance; ESG Disclosure; ESG Disclosure Metrics; ESG Ratings; ESG Reporting; Social Impact; Impact Measurement; Social Innovation; Purpose; Corporate Purpose; Corporate Social Responsibility; Strategy; Social Enterprise; Society; Accounting; Investment; Environmental Sustainability; Climate Change; Corporate Strategy; Mission and Purpose; Corporate Social Responsibility and Impact; Financial Services Industry; Chemical Industry; Technology Industry; Consumer Products Industry; Pharmaceutical Industry; North America; Europe; Japan; Australia
Serafeim, George. "Social-Impact Efforts That Create Real Value." Harvard Business Review 98, no. 5 (September–October 2020): 38–48.
- February 2018 (Revised April 2018)
- Case
Yunnan Baiyao: Transforming a Chinese State-Owned Enterprise
By: Michael Chu, William C. Kirby, Nancy Hua Dai and Yuanzhuo Wang
This case tells the story of how Wang Minghui, Chairman of Yunnan Baiyao Group since 1999, transformed a single-product traditional Chinese medicine (TCM) state-owned enterprise (SOE) into a major diversified consumer health player in China's highly competitive... View Details
Keywords: State-owned Enterprise (SOE); Traditional Chinese Medicine; Yunnan; Yunnan Baiyao; Consumer Health; Enterprise Transformation; Transformation; Health; Business History; State Ownership; Private Ownership; Business Strategy; Commercialization; Competition; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; China
Chu, Michael, William C. Kirby, Nancy Hua Dai, and Yuanzhuo Wang. "Yunnan Baiyao: Transforming a Chinese State-Owned Enterprise." Harvard Business School Case 318-078, February 2018. (Revised April 2018.)
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
Keywords: Clusters; Economics; Industry Clusters; Economy; Growth and Development; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; San Diego
Porter, Michael E. "Clusters of Innovation Initiative: San Diego." Council on Competitiveness, Washington, DC, May 2001. (Report.)
- 21 Apr 2009
- First Look
First Look: April 21, 2009
competitive standing of their domestic pharmaceutical industries. Download the paper: http://www.hbs.edu/research/pdf/09-118.pdf Capitalizing On Innovation: The Case of Japan Authors:Robert Dujarric and... View Details
Keywords: Martha Lagace
- January 1999
- Background Note
Note on the Drugstore Industry
By: David E. Bell and Ann Leamon
In response to the twin pressures of cross-channel competition and the prevalence of third-party drug plans, drugstores have changed both how they go to market and what they offer once they get there. This note reviews the history of drugstores, presents the current... View Details
- February 2010 (Revised April 2010)
- Case
Organization and Strategy at Millennium (A)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Pharmaceutical Industry; Pharmaceutical Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
- 21 Feb 2018
- Research & Ideas
When a Competitor Abandons the Market, Should You Advance or Retreat?
Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These companies may decide further... View Details
- April 1989 (Revised January 1994)
- Case
Novo Industri
By: Michael E. Porter and Michael J. Enright
Describes the structure of the insulin industry, a treatment for diabetes and Novo's strategy and competitive position in early 1982. The industry is undergoing significant change and Novo must decide how to defend and build its international position. Designed as an... View Details
Keywords: Change; Global Strategy; Industry Structures; Alliances; Competitive Strategy; Health Disorders; Pharmaceutical Industry
Porter, Michael E., and Michael J. Enright. "Novo Industri." Harvard Business School Case 389-148, April 1989. (Revised January 1994.)
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
In economic downtimes, businesses are apt to cut R&D projects that don't promise a speedy return on investment. But take a cue from smart science-based businesses, which view the recession as an opportunity to stoke up research and innovation for long-term View Details
- February 2010
- Supplement
Organization and Strategy at Millennium (B)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder CEO Mark... View Details
Keywords: Leading Change; Transformation; Decision Choices and Conditions; Crisis Management; Competitive Advantage; Commercialization; Selection and Staffing; Product Development; Organizational Change and Adaptation; Pharmaceutical Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (B)." Harvard Business School Supplement 710-418, February 2010.
- 10 Oct 2007
- First Look
First Look: First Look: October 10
Hamermesh, Faculty Chair of the Harvard Business Healthcare Initiative, discuss the barriers to personalized medicine and suggest ways to overcome them. The blockbuster model for developing drugs, the authors point out, is still what most major View Details
Keywords: Martha Lagace
- Research Summary
Overview
My focus is empirical financial accounting research, with particular interests in governance, valuation, M&A, and short-sellers. All three of my papers to date fall under the broad heading of “alternative governance mechanisms”—studies of how accounting information is... View Details
- Research Summary
Overview
My focus is empirical financial accounting research, with particular interests in governance, valuation, M&A, and short-sellers. All three of my papers to date fall under the broad heading of “alternative governance mechanisms”—studies of how accounting information is... View Details
- 08 Aug 2011
- Research & Ideas
The Death of the Global Manager
while confirming and further exploring some basic challenges that have, more or less, remained the same. "There are three core strategies that any MNC has to pursue to build layers of competitive advantage," Bartlett says.... View Details
Keywords: by Julia Hanna